OBI Logo.jpg
浩鼎將在 AACR 2024 年會 發表四篇論文
18 mars 2024 05h00 HE | OBI Pharma Inc.
台灣台北電, March 18, 2024 (GLOBE NEWSWIRE) -- 台灣浩鼎生技(4174)旗下自行開發的抗TROP2抗體藥物複合體(ADC)OBI-992,臨床前數據證明,它在多種動物實驗模式均顯示高效的抗腫瘤活性、優異的藥物動力學表現,和良好的安全性,具有發展為同類最佳抗TROP2...
OBI Logo.jpg
浩鼎将在 AACR 2024 年会   发表四篇论文
18 mars 2024 05h00 HE | OBI Pharma Inc.
台湾台北电, March 18, 2024 (GLOBE NEWSWIRE) -- 台湾浩鼎生技(4174)旗下自行开发的抗TROP2抗体药物复合体(ADC)OBI-992,临床前数据证明,它在多种动物实验模式均显示高效的抗 肿瘤活性、优异的药物动力学表现,和良好的安全性,具有发展为同类最佳抗TROP2 ADC的潜力。...
OBI Logo.jpg
OBI Pharma Announces Poster Presentations at the AACR 2024 Annual Meeting for OBI-992 and GlycOBI™ ADC platform
18 mars 2024 05h00 HE | OBI Pharma Inc.
TAIPEI, Taiwan, March 18, 2024 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (TPEx: 4174) today announced preclinical data for OBI-992, a potential best-in-class anti-TROP2 Antibody-Drug Conjugate (ADC)....
MacroGenics-Logo-(transparent-background).png
MacroGenics Provides Update on Corporate Progress and 2023 Financial Results
07 mars 2024 16h01 HE | MacroGenics, Inc.
Presentation of preliminary data from TAMARACK Phase 2 study of vobra duo in mCRPC patients expected at ASCO 2024Initiation of Phase 1 study of MGC026, MacroGenics' first topoisomerase I...
MacroGenics-Logo-(transparent-background).png
MacroGenics to Participate in Upcoming Investor Conferences
01 mars 2024 17h48 HE | MacroGenics, Inc.
ROCKVILLE, MD, March 01, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal...
MacroGenics-Logo-(transparent-background).png
MacroGenics Announces Date of Fourth Quarter 2023 Financial Results Conference Call
27 févr. 2024 17h45 HE | MacroGenics, Inc.
ROCKVILLE, MD, Feb. 27, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based...
MacroGenics-Logo-(transparent-background).png
MacroGenics to Participate in Upcoming Investor Conference
02 févr. 2024 16h30 HE | MacroGenics, Inc.
ROCKVILLE, MD, Feb. 02, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal...
MacroGenics-Logo-(transparent-background).png
MacroGenics to Participate in Upcoming Investor Conference
08 janv. 2024 16h30 HE | MacroGenics, Inc.
ROCKVILLE, MD, Jan. 08, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal...
OBI Logo.jpg
OBI-992 获FDA核准展开一/二期临床试验
03 janv. 2024 05h00 HE | OBI Pharma Inc.
台湾台北电, Jan. 03, 2024 (GLOBE NEWSWIRE) -- 台湾浩鼎生技(4174.TWO)今(3)日宣布,旗下以TROP2为标靶、自行研发的抗体药物复合体(ADC)新药OBI-992,已获美国食品药物管理局(FDA)核准一/二期临床试验申请,以评估其安全性及疗效。 ...
OBI Logo.jpg
OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-992
03 janv. 2024 05h00 HE | OBI Pharma Inc.
TAIPEI, Taiwan, Jan. 03, 2024 (GLOBE NEWSWIRE) -- OBI Pharma, a clinical stage oncology company (4174.TWO), today announced that the U.S. Food and Drug Administration (FDA) has cleared an...